Charles Schwab Investment Management Inc. Sells 63,650 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Charles Schwab Investment Management Inc. lessened its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 9.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 602,176 shares of the company's stock after selling 63,650 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.22% of Prestige Consumer Healthcare worth $43,417,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tidal Investments LLC grew its holdings in Prestige Consumer Healthcare by 4.7% in the 1st quarter. Tidal Investments LLC now owns 5,748 shares of the company's stock valued at $417,000 after buying an additional 256 shares in the last quarter. Atria Investments Inc bought a new position in Prestige Consumer Healthcare during the first quarter worth about $1,246,000. EverSource Wealth Advisors LLC raised its stake in Prestige Consumer Healthcare by 80.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company's stock worth $33,000 after purchasing an additional 208 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Prestige Consumer Healthcare by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 776 shares of the company's stock valued at $53,000 after purchasing an additional 263 shares during the period. Finally, Trust Co. of Vermont grew its position in shares of Prestige Consumer Healthcare by 18.5% during the 2nd quarter. Trust Co. of Vermont now owns 11,022 shares of the company's stock worth $759,000 after purchasing an additional 1,721 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PBH. Jefferies Financial Group reiterated a "hold" rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reiterated a "buy" rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $83.67.

Prestige Consumer Healthcare Price Performance

NYSE:PBH traded up $0.22 during mid-day trading on Monday, reaching $84.99. The stock had a trading volume of 292,955 shares, compared to its average volume of 251,520. Prestige Consumer Healthcare Inc. has a 12 month low of $57.95 and a 12 month high of $86.36. The stock has a market capitalization of $4.20 billion, a PE ratio of 20.68, a P/E/G ratio of 2.38 and a beta of 0.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock has a 50-day simple moving average of $75.66 and a two-hundred day simple moving average of $71.34.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same quarter last year, the company posted $1.07 EPS. The company's revenue for the quarter was down .9% compared to the same quarter last year. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, insider William P'pool sold 8,987 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the sale, the insider now owns 20,058 shares of the company's stock, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the transaction, the senior vice president now owns 18,835 shares of the company's stock, valued at $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.